Our work complements these findings and reveals that loss of BAX is the most potent resistance factor for MCL-1 inhibition in lymphoma, and also that such resistance can be overcome by treatment with standard-of-care chemotherapeutic drugs. This evidence concerns the gene MCL1 and lymphoma.